A 75-year-old woman presented to the emergency department of a regional hospital with progressive dyspnea for 3 months despite treatment with antibiotics and steroids in the community. There were no associated symptoms. No clear precipitating factors were identified. She did not smoke and had worked as an arable farmer but had no known exposures. Her medical history was remarkable for hypertension and a prophylactic hysterectomy 10 years previously due to a family history of ovarian cancer. Her medications included olmesartan, lansoprazole, and calcium supplements.
{"title":"The Great Mimicker, a Rare Pleural Presentation","authors":"Jack McCarthy MB BCh BAO, MRCPI , Niamh Boyle MB BCh BAO, MRCPI , Mark Coyne PhD, MB BCh BAO, MRCPI, FRCPath , Cormac McCarthy MD, PhD, FRCPI","doi":"10.1016/j.chpulm.2025.100176","DOIUrl":"10.1016/j.chpulm.2025.100176","url":null,"abstract":"<div><h3>Case Presentation</h3><div>A 75-year-old woman presented to the emergency department of a regional hospital with progressive dyspnea for 3 months despite treatment with antibiotics and steroids in the community. There were no associated symptoms. No clear precipitating factors were identified. She did not smoke and had worked as an arable farmer but had no known exposures. Her medical history was remarkable for hypertension and a prophylactic hysterectomy 10 years previously due to a family history of ovarian cancer. Her medications included olmesartan, lansoprazole, and calcium supplements.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 3","pages":"Article 100176"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2024-11-12DOI: 10.1016/j.chpulm.2024.100120
Sune Rubak MD, PhD , Anne Katrine Bak Poulsen MD , Signe Thim MD , Nagarajan Muthialu MD , Thomas Kjærgaard MD, PhD , Emil Nielsen Holck MD, PhD
Background
Methods currently used to assess and diagnose abnormalities of pediatric airways have several limitations: CT scans involve a risk of ionizing radiation and diagnostic dynamic bronchoscopies have high interobserver variability. Advanced diagnostic methods for evaluating the dynamic airway are needed to enable newer interventions (eg, airway stenting) in select children. The study objective was to investigate the feasibility of optical coherence tomography (OCT) as a measuring method that facilitates accurate, quantifiable, and real-time cross-sectional imaging of the airway.
Research Question
Is bronchoscopy-guided quantitative OCT of the lower pediatric airway a feasible method and does it increase diagnostic possibilities?
Study Design and Methods
We evaluated a series of 10 children with severe persistent respiratory symptoms with a clinical indication for diagnostic dynamic bronchoscopy (DDB). Feasibility of OCT was defined as the ability to visualize and quantify airway stenoses and dynamic airway collapse in the pediatric airway without procedural complications. Furthermore, the study included a porcine model to calculate the correction constant for the OCT measurements in air in comparison with contrast fluid.
Results
Nine children aged 0 to 14 years were included. In total, 34 airway segments were OCT scanned. Results showed that OCT is a feasible method for visualizing and quantifying stenoses of the lower pediatric airway by measuring the mean and minimum lumen areas. The correction constant of OCT in air was 1.3 (interquartile range, 1.29-1.31) in comparison with contrast. Visual assessment of the minimum lumen area stenosis by dynamic bronchoscopy significantly varies in comparison with OCT assessment (18.416%; 95% CI, 8.93-27.91; P = .0018).
Interpretation
OCT demonstrated feasibility of providing quantitative assessments of clinical manifestations including cross-sectional imaging in the pediatric airway. The correction constant for optimal quantification was calculated and provided the possibility for precise interpretation of OCT measurements. Further studies are needed to investigate safety, accuracy, and efficacy of OCT in the lower pediatric airway.
{"title":"Feasibility of Assessing the Abnormal Pediatric Airway Using Rotational Optical Coherence Tomography","authors":"Sune Rubak MD, PhD , Anne Katrine Bak Poulsen MD , Signe Thim MD , Nagarajan Muthialu MD , Thomas Kjærgaard MD, PhD , Emil Nielsen Holck MD, PhD","doi":"10.1016/j.chpulm.2024.100120","DOIUrl":"10.1016/j.chpulm.2024.100120","url":null,"abstract":"<div><h3>Background</h3><div>Methods currently used to assess and diagnose abnormalities of pediatric airways have several limitations: CT scans involve a risk of ionizing radiation and diagnostic dynamic bronchoscopies have high interobserver variability. Advanced diagnostic methods for evaluating the dynamic airway are needed to enable newer interventions (eg, airway stenting) in select children. The study objective was to investigate the feasibility of optical coherence tomography (OCT) as a measuring method that facilitates accurate, quantifiable, and real-time cross-sectional imaging of the airway.</div></div><div><h3>Research Question</h3><div>Is bronchoscopy-guided quantitative OCT of the lower pediatric airway a feasible method and does it increase diagnostic possibilities?</div></div><div><h3>Study Design and Methods</h3><div>We evaluated a series of 10 children with severe persistent respiratory symptoms with a clinical indication for diagnostic dynamic bronchoscopy (DDB). Feasibility of OCT was defined as the ability to visualize and quantify airway stenoses and dynamic airway collapse in the pediatric airway without procedural complications. Furthermore, the study included a porcine model to calculate the correction constant for the OCT measurements in air in comparison with contrast fluid.</div></div><div><h3>Results</h3><div>Nine children aged 0 to 14 years were included. In total, 34 airway segments were OCT scanned. Results showed that OCT is a feasible method for visualizing and quantifying stenoses of the lower pediatric airway by measuring the mean and minimum lumen areas. The correction constant of OCT in air was 1.3 (interquartile range, 1.29-1.31) in comparison with contrast. Visual assessment of the minimum lumen area stenosis by dynamic bronchoscopy significantly varies in comparison with OCT assessment (18.416%; 95% CI, 8.93-27.91; <em>P</em> = .0018).</div></div><div><h3>Interpretation</h3><div>OCT demonstrated feasibility of providing quantitative assessments of clinical manifestations including cross-sectional imaging in the pediatric airway. The correction constant for optimal quantification was calculated and provided the possibility for precise interpretation of OCT measurements. Further studies are needed to investigate safety, accuracy, and efficacy of OCT in the lower pediatric airway.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 2","pages":"Article 100120"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144243105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2024-12-02DOI: 10.1016/j.chpulm.2024.100125
Kristen R. Mathias MD , Ofure Akhiwu MD , Ali M. Mustafa MD , Kevin J. Psoter PhD , Edward S. Chen MD , Nisha A. Gilotra MD , Nancy W. Lin MD , John Odackal MD , Catherine A. Bonham MD , Michelle Sharp MD
Background
Sarcoidosis is a complex granulomatous disease that benefits from multidisciplinary subspecialty expertise. Inequitable access to care contributes to racial disparities in many diseases; however, to our knowledge, no studies have examined racial differences in referral times to Sarcoidosis Centers of Excellence.
Research Question
Is there an association between race and time from sarcoidosis diagnosis to referral to an independently certified, peer-reviewed World Association of Sarcoidosis and Other Granulomatous Disorders Center of Excellence? Does a referral result in a change in sarcoidosis management?
Study Design and Methods
We retrospectively reviewed all 2021 referrals to the Johns Hopkins Sarcoidosis Center of Excellence. Multivariable Cox regression evaluated the association between race and time to referral, adjusting for covariates of sex, ethnicity, referral type, referral provider, insurance provider, employment status, organ involvement, and sarcoidosis medications. Changes in sarcoidosis management including treatment changes, additional organ evaluation, and/or additional subspecialty expertise were ascertained 1 year after establishing care.
Results
At total of 207 individuals were analyzed (40% Black, 55% White, and 5% Asian and other race). Black individuals experienced longer referral delay than White individuals, with a median of 9 vs 5 years, respectively (P < .05). In multivariable analysis, the hazard of referral for White individuals was higher than for Black individuals (hazard ratio, 2.04; 95% CI, 1.48-2.82; P < .001), independent of the covariates. Sarcoidosis management changed in 78% of individuals after referral.
Interpretation
Black patients experienced significant delays in referral to a multidisciplinary subspecialty Sarcoidosis Center of Excellence compared with other racial groups. Recognition of referral delay may offer insight and opportunity to address disparities in clinical outcomes observed in Black individuals with sarcoidosis. Future multicenter studies must quantify the impact of care received through World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Centers of Excellence, define patient phenotypes in need of urgent referral, and develop targeted patient and provider outreach.
{"title":"Delays in Referral to Multidisciplinary Care for Black Individuals With Sarcoidosis","authors":"Kristen R. Mathias MD , Ofure Akhiwu MD , Ali M. Mustafa MD , Kevin J. Psoter PhD , Edward S. Chen MD , Nisha A. Gilotra MD , Nancy W. Lin MD , John Odackal MD , Catherine A. Bonham MD , Michelle Sharp MD","doi":"10.1016/j.chpulm.2024.100125","DOIUrl":"10.1016/j.chpulm.2024.100125","url":null,"abstract":"<div><h3>Background</h3><div>Sarcoidosis is a complex granulomatous disease that benefits from multidisciplinary subspecialty expertise. Inequitable access to care contributes to racial disparities in many diseases; however, to our knowledge, no studies have examined racial differences in referral times to Sarcoidosis Centers of Excellence.</div></div><div><h3>Research Question</h3><div>Is there an association between race and time from sarcoidosis diagnosis to referral to an independently certified, peer-reviewed World Association of Sarcoidosis and Other Granulomatous Disorders Center of Excellence? Does a referral result in a change in sarcoidosis management?</div></div><div><h3>Study Design and Methods</h3><div>We retrospectively reviewed all 2021 referrals to the Johns Hopkins Sarcoidosis Center of Excellence. Multivariable Cox regression evaluated the association between race and time to referral, adjusting for covariates of sex, ethnicity, referral type, referral provider, insurance provider, employment status, organ involvement, and sarcoidosis medications. Changes in sarcoidosis management including treatment changes, additional organ evaluation, and/or additional subspecialty expertise were ascertained 1 year after establishing care.</div></div><div><h3>Results</h3><div>At total of 207 individuals were analyzed (40% Black, 55% White, and 5% Asian and other race). Black individuals experienced longer referral delay than White individuals, with a median of 9 vs 5 years, respectively (<em>P</em> < .05). In multivariable analysis, the hazard of referral for White individuals was higher than for Black individuals (hazard ratio, 2.04; 95% CI, 1.48-2.82; <em>P</em> < .001), independent of the covariates. Sarcoidosis management changed in 78% of individuals after referral.</div></div><div><h3>Interpretation</h3><div>Black patients experienced significant delays in referral to a multidisciplinary subspecialty Sarcoidosis Center of Excellence compared with other racial groups. Recognition of referral delay may offer insight and opportunity to address disparities in clinical outcomes observed in Black individuals with sarcoidosis. Future multicenter studies must quantify the impact of care received through World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Centers of Excellence, define patient phenotypes in need of urgent referral, and develop targeted patient and provider outreach.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 2","pages":"Article 100125"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2024-11-08DOI: 10.1016/j.chpulm.2024.100117
Domingo J. Franco-Palacios MD , Rebecca Priebe NP , Jane Simanovski PhD, NP , Lisa L. Allenspach MD , Lisa Stagner DO , Lisa K. Waynick PA , Yichu Wang BS , Mei Lu BS , Shraddha Desai MD , Daniel Kapadia MD , Avi Cohen MD
Background
Many bronchoscopic lung volume reduction (BLVR) studies have excluded patients meeting the listing criteria for lung transplantation (LT).
Research Question
What are the outcomes of BLVR in a sicker group of patients with emphysema compared with patients not meeting the criteria for LT listing?
Study Design and Methods
This was a real-world retrospective study (June 2018 to December 2022) assessing the effect of BLVR in patients with severe emphysema considered for LT. FEV1, FVC, diffusing capacity for carbon monoxide, symptoms, and 6-minute walk distance (6-MWD) were measured at baseline and 45 days and 6 months after BLVR.
Results
Of 76 fully evaluated patients (median age, 62 years; 60% female), 42 underwent BLVR (30 sicker patients met the criteria for LT listing). At baseline, patients that met the criteria for listing had shorter baseline 6-MWD (234.72 ± 68.86, P < .001), higher BODE Index score (6.79 ± 1.11, P = .001), and lower FEV1 (617.5 ± 139.2 mL, P = .005). All patients treated with BLVR experienced a decrease in BODE Index and Borg dyspnea by scores −0.5 to −2 points, respectively. Diffusing capacity for carbon monoxide % predicted increased by 4.5%, FEV1 increased by 115 mL, FVC increased by 450 mL, and 6-MWD increased by 20 meters. In the sicker group, FEV1 at 45 days after BLVR increased by 180.8 ± 231 mL (FEV1 % predicted 5.84 ± 5.66) compared with baseline; a persistent effect was seen at 6 months in 62% of patients with available data (18 of 30). Median hospital length of stay was 3.27 ± 3.07 days. Endobronchial valves were removed in 6 patients (3 in each group) due to complications. The pneumothorax rate was 24% (10 of 42; 5 in each group).
Interpretation
Improvement in lung function after BLVR was observed regardless of disease severity. BLVR might represent an alternative to LT for some patients.
{"title":"Bronchoscopic Lung Volume Reduction","authors":"Domingo J. Franco-Palacios MD , Rebecca Priebe NP , Jane Simanovski PhD, NP , Lisa L. Allenspach MD , Lisa Stagner DO , Lisa K. Waynick PA , Yichu Wang BS , Mei Lu BS , Shraddha Desai MD , Daniel Kapadia MD , Avi Cohen MD","doi":"10.1016/j.chpulm.2024.100117","DOIUrl":"10.1016/j.chpulm.2024.100117","url":null,"abstract":"<div><h3>Background</h3><div>Many bronchoscopic lung volume reduction (BLVR) studies have excluded patients meeting the listing criteria for lung transplantation (LT).</div></div><div><h3>Research Question</h3><div>What are the outcomes of BLVR in a sicker group of patients with emphysema compared with patients not meeting the criteria for LT listing?</div></div><div><h3>Study Design and Methods</h3><div>This was a real-world retrospective study (June 2018 to December 2022) assessing the effect of BLVR in patients with severe emphysema considered for LT. FEV<sub>1</sub>, FVC, diffusing capacity for carbon monoxide, symptoms, and 6-minute walk distance (6-MWD) were measured at baseline and 45 days and 6 months after BLVR.</div></div><div><h3>Results</h3><div>Of 76 fully evaluated patients (median age, 62 years; 60% female), 42 underwent BLVR (30 sicker patients met the criteria for LT listing). At baseline, patients that met the criteria for listing had shorter baseline 6-MWD (234.72 ± 68.86, <em>P</em> < .001), higher BODE Index score (6.79 ± 1.11, <em>P</em> = .001), and lower FEV<sub>1</sub> (617.5 ± 139.2 mL, <em>P</em> = .005). All patients treated with BLVR experienced a decrease in BODE Index and Borg dyspnea by scores −0.5 to −2 points, respectively. Diffusing capacity for carbon monoxide % predicted increased by 4.5%, FEV<sub>1</sub> increased by 115 mL, FVC increased by 450 mL, and 6-MWD increased by 20 meters. In the sicker group, FEV<sub>1</sub> at 45 days after BLVR increased by 180.8 ± 231 mL (FEV<sub>1</sub> % predicted 5.84 ± 5.66) compared with baseline; a persistent effect was seen at 6 months in 62% of patients with available data (18 of 30). Median hospital length of stay was 3.27 ± 3.07 days. Endobronchial valves were removed in 6 patients (3 in each group) due to complications. The pneumothorax rate was 24% (10 of 42; 5 in each group).</div></div><div><h3>Interpretation</h3><div>Improvement in lung function after BLVR was observed regardless of disease severity. BLVR might represent an alternative to LT for some patients.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 2","pages":"Article 100117"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144298043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-02-07DOI: 10.1016/j.chpulm.2025.100147
Ricardo G. Figueiredo PhD , Fernando Holguin MSc , Márcia M.M. Pizzichini PhD , Gabriela P. Pinheiro PhD , Vanessa Arata MD , Maisa F.M. Leal , Cinthia V.N. Santana PhD , José de Bessa Junior PhD , Álvaro A. Cruz PhD
{"title":"Connecting the Dots Between Asthma Control and Frailty in Older Adults With Moderate to Severe Asthma","authors":"Ricardo G. Figueiredo PhD , Fernando Holguin MSc , Márcia M.M. Pizzichini PhD , Gabriela P. Pinheiro PhD , Vanessa Arata MD , Maisa F.M. Leal , Cinthia V.N. Santana PhD , José de Bessa Junior PhD , Álvaro A. Cruz PhD","doi":"10.1016/j.chpulm.2025.100147","DOIUrl":"10.1016/j.chpulm.2025.100147","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 2","pages":"Article 100147"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-03-12DOI: 10.1016/j.chpulm.2025.100162
Seigo Miyoshi MD, PhD, Mayuko Semba MD, Miyuki Tanabe MD, Chika Sato MD, Akira Watanabe MD, PhD, Ryoji Ito MD, PhD, Mari Kubota, Masahiro Abe MD, PhD
Background
Previous studies have identified several risk factors for death because of TB, including advanced age, HIV coinfection, multidrug-resistant TB, malnutrition, low activities of daily living, and comorbidities. In Japan, the incidence of TB and TB-related deaths is consistently higher among older individuals. However, few studies have evaluated the risk factors for death in older adult patients with TB.
Research Question
What are the risk factors for death among older adults with TB?
Study Design and Methods
This prospective cohort study included data on consecutive older adult patients (aged ≥ 65 years) who were admitted for treatment of TB between October 2016 and April 2022. We collected data on patient characteristics, chest radiography findings, and laboratory data and assessed whether these parameters were associated with patient death. We also examined the risk factors associated with TB-related and TB-unrelated deaths as a subanalysis.
Results
Multivariate Cox proportional hazards analysis showed that performance status (hazard ratio [HR], 1.434; 95% CI, 1.051-1.956; P = .023), corticosteroid use (HR, 2.679; 95% CI, 1.374-5.221; P = .004), and serum albumin levels (HR, 0.434; 95% CI, 0.235-0.804; P = .008) were significantly correlated with all-cause mortality. Subanalyses demonstrated that performance status was significantly correlated with TB-related death (HR, 2.048; 95% CI, 1.459-2.874; P < 0.001), whereas advanced age (HR, 1.073; 95% CI, 1.008-1.142; P = .027), corticosteroid use (HR, 4.131; 95% CI, 1.783-9.575; P < .001), and serum albumin levels (HR, 0.435; 95% CI, 0.225-0.842; P = .014) were significantly correlated with TB-unrelated deaths.
Interpretation
The evaluation of daily activity, physical ability, immune status, and nutritional status is considered an important factor directly related to prognosis in the treatment of TB in older adults. Large-scale prospective studies should be conducted in the future.
{"title":"Assessment of Risk Factors for Death in Older Adult Patients With TB in Japan","authors":"Seigo Miyoshi MD, PhD, Mayuko Semba MD, Miyuki Tanabe MD, Chika Sato MD, Akira Watanabe MD, PhD, Ryoji Ito MD, PhD, Mari Kubota, Masahiro Abe MD, PhD","doi":"10.1016/j.chpulm.2025.100162","DOIUrl":"10.1016/j.chpulm.2025.100162","url":null,"abstract":"<div><h3>Background</h3><div>Previous studies have identified several risk factors for death because of TB, including advanced age, HIV coinfection, multidrug-resistant TB, malnutrition, low activities of daily living, and comorbidities. In Japan, the incidence of TB and TB-related deaths is consistently higher among older individuals. However, few studies have evaluated the risk factors for death in older adult patients with TB.</div></div><div><h3>Research Question</h3><div>What are the risk factors for death among older adults with TB?</div></div><div><h3>Study Design and Methods</h3><div>This prospective cohort study included data on consecutive older adult patients (aged ≥ 65 years) who were admitted for treatment of TB between October 2016 and April 2022. We collected data on patient characteristics, chest radiography findings, and laboratory data and assessed whether these parameters were associated with patient death. We also examined the risk factors associated with TB-related and TB-unrelated deaths as a subanalysis.</div></div><div><h3>Results</h3><div>Multivariate Cox proportional hazards analysis showed that performance status (hazard ratio [HR], 1.434; 95% CI, 1.051-1.956; <em>P</em> = .023), corticosteroid use (HR, 2.679; 95% CI, 1.374-5.221; <em>P</em> = .004), and serum albumin levels (HR, 0.434; 95% CI, 0.235-0.804; <em>P</em> = .008) were significantly correlated with all-cause mortality. Subanalyses demonstrated that performance status was significantly correlated with TB-related death (HR, 2.048; 95% CI, 1.459-2.874; <em>P</em> < 0.001), whereas advanced age (HR, 1.073; 95% CI, 1.008-1.142; <em>P</em> = .027), corticosteroid use (HR, 4.131; 95% CI, 1.783-9.575; <em>P</em> < .001), and serum albumin levels (HR, 0.435; 95% CI, 0.225-0.842; <em>P</em> = .014) were significantly correlated with TB-unrelated deaths.</div></div><div><h3>Interpretation</h3><div>The evaluation of daily activity, physical ability, immune status, and nutritional status is considered an important factor directly related to prognosis in the treatment of TB in older adults. Large-scale prospective studies should be conducted in the future.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 2","pages":"Article 100162"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144243103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-03-05DOI: 10.1016/j.chpulm.2025.100161
Kim Styrvoky MD , Xinhui Duan PhD
{"title":"Cumulative Personal Radiation Exposure for a Single Pulmonary Proceduralist Over 1 Year","authors":"Kim Styrvoky MD , Xinhui Duan PhD","doi":"10.1016/j.chpulm.2025.100161","DOIUrl":"10.1016/j.chpulm.2025.100161","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 2","pages":"Article 100161"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144243083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号